Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
Status:
Completed
Trial end date:
2019-11-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of ibrutinib in combination
with rituximab in participants with Waldenström's macroglobulinemia (WM).